Evidence map›Paper›PMID 28164407›Full record

ArticleAddiction (Abingdon, England)2017

Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction.

Matthew J Worley, Keith G Heinzerling, Steven Shoptaw, Walter Ling

Abstract readMulticenter Study
In one paragraph

Article in Addiction (Abingdon, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Matthew J WorleyDepartment of Psychiatry, University of California, San Diego, CA, USA.
Keith G HeinzerlingDepartment of Family Medicine, University of California, Los Angeles, CA, USA.
Steven ShoptawDepartment of Family Medicine, University of California, Los Angeles, CA, USA.
Walter LingDepartment of Psychiatry, University of California, Los Angeles, CA, USA.
University of California, Los Angeles · USUniversity of California, San Diego · US

Funding

UCLA Rapid, Relevant, Rigorous Implementation Science HubP30MH058107 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RAPHAEL J LANDOVITZ · 1997 to 2026
$53.5M
The National Drug Abuse Treatment Clinical Trials NetworkU10DA013045 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LING, WALTER NMN · 1999 to 2015
$52.6M
CU PARTNERS: NY/LONG ISLAND REGIONAL NODEU10DA013035 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI NUNES, EDWARD V., ROTROSEN, JOHN P · 2001 to 2015
$47.6M
Clinical Trials Network, Ohio Valley Node U10DA013732U10DA013732 · NIDA · UNIVERSITY OF CINCINNATI · PI WINHUSEN, T JOHN · 2000 to 2015
$45.0M
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHEN, IRVIN S.Y. · 1991 to 2018
$39.9M
Southern Consortium Node of the Clinical Trials NetworkU10DA013727 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T. · 2000 to 2015
$34.4M
The National Drug Abuse Treatment Clinical Trials Network (U10)U10DA015831 · NIDA · MC LEAN HOSPITAL (BELMONT, MA) · PI CARROLL, KATHLEEN M., WEISS, ROGER D. · 2002 to 2015
$28.8M
CLINICAL TRIALS NETWORK: PACIFIC NORTHWEST NODEU10DA013714 · NIDA · UNIVERSITY OF WASHINGTON · PI DONOVAN, DENNIS MICHAEL, ROLL, JOHN M. · 2001 to 2015
$25.5M
Western States Node of the National Drug Abuse Treatment Clinical Trials NetworkU10DA015815 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MCCARTY, DENNIS, SORENSEN, JAMES L · 2002 to 2015
$25.2M
CLINICAL TRIAL RESEARCH PROJECT COREU10DA020036 · NIDA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DALEY, DENNIS C · 2005 to 2015
$14.1M
Randomized Trial of Ibudilast for Methamphetamine DependenceR01DA035054 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HEINZERLING, KEITH GREGORY · 2012 to 2017
$3.3M
Varenicline for Methamphetamine DependenceR01DA030577 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SHOPTAW, STEVEN J · 2011 to 2013
$1.8M
NIAID NIH HHS P30 AI028697NIDA NIH HHS K23 DA039348NIDA NIH HHS L30 DA038321NIDA NIH HHS R01 DA030577NIDA NIH HHS R01 DA035054NIDA NIH HHS T32 DA026400NIDA NIH HHS U10 DA013035NIDA NIH HHS U10 DA013045NIDA NIH HHS U10 DA013714NIDA NIH HHS U10 DA013727NIDA NIH HHS U10 DA013732NIDA NIH HHS U10 DA015815NIDA NIH HHS U10 DA015831NIDA NIH HHS U10 DA020036NIMH NIH HHS P30 MH058107
6 · The paper itself

Abstract

BACKGROUND AND

aimsBuprenorphine-naloxone (BUP-NLX) can be used to manage prescription opioid addiction among persons with chronic pain, but post-treatment relapse is common and difficult to predict. This study estimated whether changes in pain over time and pain volatility during BUP-NLX maintenance would predict opioid use during the taper BUP-NLX taper.

designSecondary analysis of a multi-site clinical trial for prescription opioid addiction, using data obtained during a 12-week BUP-NLX stabilization and 4-week BUP-NLX taper.

settingCommunity clinics affiliated with a national clinical trials network in 10 US cities.

participantsSubjects with chronic pain who entered the BUP-NLX taper phase (n = 125) with enrollment occurring from June 2006 to July 2009 (52% male, 88% Caucasian, 31% married). MEASUREMENTS: Outcomes were weekly biologically verified and self-reported opioid use from the 4-week taper phase. Predictors were estimates of baseline severity, rate of change and volatility in pain from weekly self-reports during the 12-week maintenance phase.

findingsControlling for baseline pain and treatment condition, increased pain [odds ratio (OR) = 2.38, P = 0.02] and greater pain volatility (OR = 2.43, P = 0.04) predicted greater odds of positive opioid urine screen during BUP-NLX taper. Increased pain (IRR = 1.40, P = 0.04) and greater pain volatility [incidence-rate ratio (IRR) = 1.66, P = 0.009] also predicted greater frequency of self-reported opioid use.

conclusionsAdults with chronic pain receiving out-patient treatment with buprenorphine-naloxone (BUP-NLX) for prescription opioid addiction have an elevated risk for opioid use when tapering off maintenance treatment. Those with relative persistence in pain over time and greater volatility in pain during treatment are less likely to sustain abstinence during BUP-NLX taper.

Indexed as

AdultBuprenorphineChronic PainDrug Therapy, CombinationFemaleHumansMaleNaloxoneNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersSeverity of Illness IndexTreatment OutcomeUnited StatesBuprenorphineNaloxoneNarcotic AntagonistsBuprenorphine-naloxonechronic painmultilevel modelingpredictionprescription opiatestreatment outcomes

Identifiers

PMID28164407
PMCPMC5461207
OpenAlexW2585086433

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.